Shenzhen Salubris Pharmaceuticals Co., Ltd. founded in 1998 and listed on the Shenzhen Stock Exchange in 2009 (stock code: 002294) is an innovation-driven pharmaceutical company based in China and extended globally. The company has established a plurality of R&D centers both in China and the United States covering the whole industry chain and connecting global innovative resources to study pathogenesis, explore therapies and develop innovative drugs.

Based on patients' benefits, Salubris meets the unfulfilled clinical needs by focusing on the cardio-cerebrovascular field to develop a product system with strategic coordination of chemical medicines, biological medicines and medical devices, provides superior comprehensive solutions for patients, and explores innovative drugs in fields of hypoglycemia, anti-tumor, orthopaedics, nephropathy and anti-infection to construct the original innovation system of medicines.

With evidence-based medicine as the core, Salubris has professional marketing teams to promote innovative products to more than 30 countries and regions including China, the United States, Germany, France, Japan and so on.

The mission of "providing outstanding pharmaceutical products for human health" drives our continuous innovation.

We are committed to maintaining patient health by scientific improvement of life quality.

Eight Industry Bases

Salubris (Baoan) Medicine R&D and Industrialization Base

Salubris (Daya Bay) Oral Preparation and API Industrialization Base

Salubris (Pingshan) Medical Device and Innovative Drug Industrialization Base

Salubris (Chengdu) Biopharmaceutical R&D Base

Salubris (Suzhou) Biopharmaceutical Industrialization Base

Salubris (Shandong) Pharmaceutical Intermediate and API Industrialization Base

Salubris (Suzhou) Huanchen Medical Device Industry Base

Beijing Salubris Medtech Co.,Ltd. and Industry Base

深圳信立泰药业股份有限公司（以下简称“信立泰”）成立于1998年，2009年在深交所上市（股票代码：002294），是一家立足中国、面向全球、研产销一体化的创新驱动型医药企业。信立泰坚守“为人类健康提供卓越的医药产品”的神圣使命，以优质创新产品和循证医学推广为核心竞争力，努力打造成为以心脑血管为主的慢病领域龙头企业。

信立泰先后承担“十一五”“十二五”“十三五”国家重大专项及国家、省、市的重大科技项目60 余项，3次获“中国专利金奖”，荣获“国家技术创新示范企业”“中国医药研发产品线最佳工业企业”等荣誉。

八大产业基地

信立泰（宝安）药物研发及产业化基地

信立泰（大亚湾）口服制剂及原料药产业化基地

信立泰（坪山）药物和医疗器械研发及产业化基地

信立泰（成都）生物药研发基地

信立泰（苏州）生物药产业化基地

信立泰（山东）药物中间体及原料药产业化基地

信立泰（苏州）桓晨医疗器械产业基地

北京信立泰医疗器械有限公司及产业基地

以集团化、国际化为导向，通过技术合作+投资并购多途径精准布局全球产业链。